Phase 2Terminated
Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy
- Sponsor
- ConjuChem (Industry)
- Enrolment
- 73 enrolled
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- CJC-1134-PC Injection; Weekly placebo for CJC-1134-PC Injection
- Ages
- adults, older adults
- Registry
- NCT01514149
Full record on ClinicalTrials.gov
From the registry
DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.
Primary outcomes
- Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18
History
Results first posted
Last registry update
Study completion
Primary completion
Registered
Started